gut healing

Gut Restoration Protocol

Mucosal Repair, Tight Junction Integrity & Microbiome Support

strong evidence

A comprehensive peptide protocol targeting intestinal barrier repair, mucosal healing, and inflammation reduction. This evidence-based approach utilizes gut-native peptides to restore epithelial integrity and address the root causes of leaky gut, IBS, and chronic digestive dysfunction.

beginner

Difficulty

1-2 weeks

First Results

8-12 weeks

Duration

$120-450

Monthly Cost

Overview

Who This Protocol
Is Designed For

“Your gut barrier is a single-cell-thick layer standing between your bloodstream and trillions of microbes. When this barrier fails, systemic inflammation follows. BPC-157 and targeted peptides can restore tight junction integrity and heal damaged mucosa at the cellular level.”

Ideal Candidates

Those with diagnosed or suspected leaky gut/intestinal permeability
Individuals with IBS, IBD, or chronic digestive symptoms
People with food sensitivities suggesting barrier dysfunction
Those recovering from NSAID damage, antibiotic courses, or gut infections
Anyone with autoimmune conditions potentially linked to gut permeability

Contraindications

Active gastrointestinal bleeding or perforation
Undiagnosed severe abdominal pain (requires medical evaluation first)
Active GI malignancy
Pregnancy or breastfeeding

Expected Outcome

Most users report reduced bloating and improved digestion within 1-2 weeks. By 4-6 weeks, food sensitivities often decrease and systemic symptoms (brain fog, joint pain, skin issues) related to gut permeability begin resolving. Full mucosal healing typically requires 8-12 weeks.

The Science

Mechanism of Action
& Evidence Base

How It Works

Peptide

Mechanism

Biological Rationale

Targeted metabolic intervention at the receptor level

BPC-157 is a stable gastric pentadecapeptide native to human gastric juice that maintains GI mucosa integrity through multiple pathways including Egr-1 gene stimulation, FAK-paxillin pathway activation, and modulation of the nitric oxide system. KPV, a tripeptide fragment of alpha-MSH, reduces intestinal inflammation by inhibiting pro-inflammatory mechanisms in intestinal epithelial cells and macrophages. Together, these peptides address both structural repair and inflammatory drivers of gut dysfunction.

The intestinal barrier depends on tight junctions between epithelial cells, a healthy mucus layer, and balanced immune surveillance. Modern stressors (NSAIDs, alcohol, processed foods, stress) damage these systems. Peptide therapy provides the specific signaling molecules needed for repair—signals the body may be unable to generate adequately when chronically inflamed.

Human Studies

150

Animal Studies

In Vitro Studies

strong

Evidence Strength

Key Findings

BPC-157 demonstrated safety in human inflammatory bowel disease trials with no toxicity reported
BPC-157 is uniquely stable in human gastric juice for 24+ hours, enabling oral administration
KPV delivered orally significantly reduced inflammation and tissue damage in colitis models (Gastroenterology, 2007)
Larazotide acetate reduced symptoms in Phase 2/3 celiac trials by blocking zonulin-mediated permeability
BPC-157 successful in healing GI ulcers, fistulas, and anastomosis sites in preclinical models

Limitations

Most BPC-157 research is preclinical; human trial data is limited though promising
KPV human dosing not yet established; preclinical data guides current use
Long-term effects beyond 12 weeks not extensively studied

Protocol Tiers

Choose Your
Protocol Level

Best For

Those new to peptides, mild-moderate gut issues, or seeking straightforward gut support

Cycle Duration

8-12 weeks

Off-Cycle

4 weeks minimum

Single peptide approach using BPC-157 for general gut healing and barrier repair—the most versatile and well-researched option

Peptide

BPC-157

Dose Range

250-500 mcg

Frequency

twice-daily

Route

oral

Duration

8-12 weeks

Timing

30-60 minutes before meals on empty stomach (oral) or any time (injectable)

Special Instructions

Oral capsules or liquid preferred for direct GI contact. If using injectable, subcutaneous in abdomen brings peptide closer to target tissue. Can also use sublingual for partial local + systemic effect.

When to Stop

Severe abdominal pain (not typical; requires evaluation)
Blood in stool (not caused by protocol but requires workup)
Allergic reaction to peptide

Peptide Database

Gut Restoration Protocol

Who This ProtocolIs Designed For

Ideal Candidates

Contraindications

Mechanism of Action& Evidence Base

Peptide

Key Findings

Limitations

Choose YourProtocol Level

BPC-157

When to Stop

Who This Protocol
Is Designed For

Mechanism of Action
& Evidence Base

Choose Your
Protocol Level